Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Phase 4
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Carcinoma
Both
Renal Cell Carcinoma
Trial Information
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
No sampling. All eligible patients will be included.
Inclusion Criteria:
Metastatic renal cell carcinoma
Exclusion Criteria:
None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Overall survival from initiation of first systemic anticancer therapy
Outcome Time Frame:
8 months
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Denmark: Danish Medicines Agency
Study ID:
A6181203
NCT ID:
NCT01339962
Start Date:
April 2011
Completion Date:
December 2013
Related Keywords:
- Renal Cell Carcinoma
- Metastatic renal cell carcinoma
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
